-
Product Insights
NewBrain Derived Neurotrophic Factor – Drugs In Development, 2024
The Brain Derived Neurotrophic Factor pipeline drugs market research report outlays comprehensive information on the Brain Derived Neurotrophic Factor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Cardiovascular, Metabolic Disorders, and Ear Nose Throat Disorders which include indications of Alzheimer's Disease, Parkinson's Disease, Ischemic Stroke, Cardiac Arrest, Obesity, Deafness, and Hearing Disorders. It also...
-
Product Insights
NewBrain+ ApS Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Brain+ ApS Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Brain+ ApS (Brain+) is a developer of application for brain training. It develops technologies and tools that help to reach critical goals for brain training. Brain+ is headquartered in Copenhagen, Denmark. GlobalData's Medical Devices company profile report, “Brain+ ApS Pipeline Insight and Competitive Landscape, 2023" provides information about the company overview and analysis on their pipeline products. This company profile...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-07799544 in Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-07799544 in Brain Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF-07799544 in Brain Tumor Drug Details: PF-07799544 (ARRY-134) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ronopterin in Traumatic Brain Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ronopterin in Traumatic Brain Injury report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ronopterin in Traumatic Brain Injury Drug Details: Ronopterin (VAS-203) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CIGB-128 in Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CIGB-128 in Brain Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CIGB-128 in Brain Tumor Drug Details: CIGB-128 is under investigation for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azeliragon in Refractory Brain Metastasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azeliragon in Refractory Brain Metastasis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azeliragon in Refractory Brain Metastasis Drug Details: Azeliragon is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vaccine For Oncology in Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vaccine For Oncology in Brain Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vaccine For Oncology in Brain Tumor Drug Details: Plasmodium...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OKL-1111 in Brain Hemorrhage
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OKL-1111 in Brain Hemorrhage report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OKL-1111 in Brain Hemorrhage Drug Details: OKL-1111 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Elzovantinib in Metastatic Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elzovantinib in Metastatic Brain Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Elzovantinib in Metastatic Brain Tumor Drug Details: Elzovantinib (TPX-0022) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SL-22P in Refractory Brain Metastasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SL-22P in Refractory Brain Metastasis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SL-22P in Refractory Brain Metastasis Drug Details: SL-22P is under...